comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 17:03:13 - browse：23644

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： AI can decode, harness the power of the humane immune system

WSS

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Histogen: Failed biotech offers rare public look inside

Physician executives need more than on

VC firm General Catalyst wants to buy a health system

Most antidepressants don't work on kids, teens, study finds

AI for drug discovery: Experts on separating hype from reality

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medical records are filled with copy

The creative science of coining drug names

Anesthesiologist group: stop taking Ozempic before surgery

A Q&A with the global head of Boehringer Ingelheim's innovation unit

United colonoscopy coverage change 'may cost lives,' doctors say

FDA rejects Alnylam's heart disease treatment over insufficient data

Anesthesiologist group: stop taking Ozempic before surgery

Crowdfunding for medical bills sidesteps core problem, author says

BioMarin wins approval for gene therapy to treat hemophilia A

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

explore

Chemotherapy before breast cancer surgery might fuel metastasis

Empower primary care with adequate payments and technology

3 questions for the future of Biden's cancer moonshot

The effects of a landmark ruling on DNA ownership are becoming clearer

Analysis of telehealth claims data suggest service duplication

Has Bernie Sanders reached the limit of his pharma bullying effort?

focus

hotspot

hotspot

leisure time